MetLife (MET)
(Delayed Data from NYSE)
$78.43 USD
+0.01 (0.01%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $78.42 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
A Value F Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$78.43 USD
+0.01 (0.01%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $78.42 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
A Value F Growth F Momentum C VGM
Zacks News
Everest Group Q3 Earnings, Revenues Miss on Higher Catastrophe Loss
by Zacks Equity Research
EG's Q3 results reflect above-average cat loss as well as lower premiums in Insurance. Higher premiums in Reinsurance and improved net investment income limited the downside.
Company News for Nov 1, 2024
by Zacks Equity Research
Companies In The Article Are: MET,CI, BMY, MO
MetLife Q3 Earnings Miss on Weak Group Benefits Unit & High Costs
by Zacks Equity Research
MET's third-quarter earnings suffer from higher expenses and a lower recurring interest margin in RIS.
Compared to Estimates, MetLife (MET) Q3 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for MetLife (MET) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
MetLife (MET) Misses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
MetLife (MET) delivered earnings and revenue surprises of -10.65% and 4.66%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
MetLife Stock Before Q3 Earnings: Buy Now or Wait for Results?
by Zacks Equity Research
MET's third-quarter earnings are likely to have benefited from rising premiums and investment income.
Q3 Showdown: Can These 5 Insurance Stocks Beat the Estimates?
by Kaibalya Pravo Dey
Increasing rates, underwriting practices and other factors are expected to have benefited insurance players in the third quarter. AFL, MET, ALL, PRU & AXS will release earnings on Oct. 30.
5 Insurers Poised to Outperform Estimates This Earnings Season
by Tanuka De
Better pricing, exposure growth, accelerated digitalization and sturdy capital are expected to help BRK.B, MET, LNC, WTW and AFL outperform third-quarter earnings estimates.
Exploring Analyst Estimates for MetLife (MET) Q3 Earnings, Beyond Revenue and EPS
by Zacks Equity Research
Besides Wall Street's top -and-bottom-line estimates for MetLife (MET), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2024.
MetLife (MET) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
MetLife (MET) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Want Better Returns? Don?t Ignore These 2 Finance Stocks Set to Beat Earnings
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Should You Invest in the SPDR S&P Insurance ETF (KIE)?
by Zacks Equity Research
Sector ETF report for KIE
This is Why MetLife (MET) is a Great Dividend Stock
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does MetLife (MET) have what it takes? Let's find out.
THG Stock Trading at a Premium to Industry: Should You Buy?
by Tanuka De
THG stands to gain from growth in the Core Commercial and Specialty segments, stable retention, better pricing, strong market presence and solid capital position.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Is iShares MSCI USA Equal Weighted ETF (EUSA) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for EUSA
MetLife (MET) Could Be a Great Choice
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does MetLife (MET) have what it takes? Let's find out.
PRI Near 52-Week High: Should You Add the Stock to Your Portfolio Now?
by Zacks Equity Research
Primerica's strong licensed sales force, ensuring sales growth and policy persistency, and decision to exit the senior health market poise it well for growth.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
MET vs. ZURVY: Which Stock Is the Better Value Option?
by Zacks Equity Research
MET vs. ZURVY: Which Stock Is the Better Value Option?
Is MetLife (MET) Outperforming Other Finance Stocks This Year?
by Zacks Equity Research
Here is how MetLife (MET) and Popular (BPOP) have performed compared to their sector so far this year.
Is MetLife (MET) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Analyzing MetLife Stock: Is Buy Strategy the Right Move?
by Zacks Equity Research
MET remains well-poised for growth, attributed to strength in the EMEA segment, divestiture of underperforming businesses and a commendable financial stand.
Are Investors Undervaluing CNO Financial Group (CNO) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Are You Looking for a High-Growth Dividend Stock?
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does MetLife (MET) have what it takes? Let's find out.